Invasive fungal infections in children

Dornbusch HJ, Manzoni P, Roilides E, Walsh TJ, Groll AH
Source: The Aspergillus Website - articles - Category: Respiratory Medicine Source Type: news

Related Links:

AbstractPurpose of ReviewThis review summarizes current treatment options for echinocandin-resistantCandida spp. (ERC) and azole-resistantAspergillus fumigatus (ARAF), emphasizing recent in vitro/in vivo data, clinical reports, and consensus statements.Recent FindingsAdvances in ERC and ARAF treatment are limited to specific antifungal combinations and dose optimization but remain reliant on amphotericin products. Although novel antifungals may provide breakthroughs in the treatment of resistant fungi, these agents are not yet available. Early identification and appropriate treatment remain a paramount, albeit elusive, tas...
Source: Current Fungal Infection Reports - Category: Infectious Diseases Source Type: research
Authors: Hatinguais R, Willment JA, Brown GD Abstract Fungi are opportunistic pathogens that infect immunocompromised patients and are responsible for an estimated 1.5 million deaths every year. The antifungal innate immune response is mediated through the recognition of pathogen-associated molecular patterns (PAMPs) by the host's pattern recognition receptors (PRRs). PRRs are immune receptors that ensure the internalisation and the killing of fungal pathogens. They also mount the inflammatory response, which contributes to initiate and polarise the adaptive response, controlled by lymphocytes. Both the innate and ...
Source: Current Topics in Microbiology and Immunology - Category: Microbiology Tags: Curr Top Microbiol Immunol Source Type: research
Conclusion: The blockade of PD-1 on postsepsis aspergillosis presumably reinvigorated exhausted antigen-presenting cells and T cells by upregulating CD86 expression and IFN-γ production, and dampened IL-10 production, which consequently leaded to the attenuation of secondary aspergillosis. The adjunctive anti-PD-1 therapy may become a promising strategy for the advanced immunotherapy against lethal fungal infection.
Source: Shock - Category: Emergency Medicine Tags: Basic Science Aspects Source Type: research
This study aimed to assay both aflatoxin (AFs) and ochratoxin A (OTA) contamination using an integrative method of morphological identification, molecular detection, and chromatography analysis on dried chili provided from traditional and modern markets in Indonesia. The results showed that total fungal infection ranged from 1-408 × 103 CFU/g. Eighty percent of the chili obtained from both the traditional and the modern markets were infected by Aspergillus spp., in which 50% of the infections were identified as A. parasiticus and A. flavus. A complete set of targeted genes involved in AF production and OTA were d...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
Conclusion: Luliconazole versus amphotericin B, voriconazole, posaconazole and caspofungin is a potent antifungal for Aspergillus Nigri complex. The in vitro extremely antifungal efficacy against black Aspergillus strains of luliconazole, is different from those of other used antifungals. PMID: 32148683 [PubMed]
Source: Iranian Journal of Microbiology - Category: Microbiology Tags: Iran J Microbiol Source Type: research
AbstractPurpose of ReviewTo describe the clinical features, diagnosis, and treatment of angioinvasive fungal infections.Recent FindingsCandida auris is a recently discovered species with multi- to pan-drug resistance to azoles, amphotericin B, and echinocandins. The SECURE trial showed that isavuconazole was non-inferior to voriconazole for treatment ofAspergillus. Additionally, the VITAL study showed that there was no difference in mortality between those treated with either isavuconazole or amphotericin B. Isavuconazole is now approved by the FDA for the treatment ofAspergillus andMucor.SummaryInvasive fungal infections ...
Source: Current Dermatology Reports - Category: Dermatology Source Type: research
Purpose of review This review aims to update on recent findings about epidemiology, risk factors and therapeutic options for fungi causing skin and soft tissue infections. The latest data on emerging antifungal resistance are also discussed. Recent findings In parallel with increased use of immunosuppression, the incidence of fungal infections is also on rise. This increase involves not only systemic infections but also infections with primary and secondary skin involvement. Antifungal resistance has become a major issue and covers several fungal pathogens including dermatophytes, Candida spp. and, Aspergillus fumigat...
Source: Current Opinion in Infectious Diseases - Category: Infectious Diseases Tags: SKIN AND SOFT TISSUE INFECTIONS: Edited by Matteo Bassetti Source Type: research
Tuesday, March 3, 2020 - 16:20Slide presentation
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news
Saturday, February 29, 2020 - 13:03Slide presentation
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news
Hematopoietic cell transplantation (HCT) is associated with a high risk of invasive fungal infections (IFIs). Fluconazole is approved in the United States for Candida prophylaxis during HCT, but it does not provide coverage against molds [1]. Voriconazole, a broad-spectrum triazole active against Candida and Aspergillus species, has been increasingly used for antifungal prophylaxis in patients undergoing high-risk HCT, such as cord blood HCT and ex vivo T cell-depleted HCT recipients [2-4]. In a randomized trial of voriconazole versus fluconazole prophylaxis in standard-risk HCT recipients, the overall rates of IFI and fun...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Aspergillus | Children | Fungal Infections | Respiratory Medicine | Websites